J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

Mr Rajarshi (Rishi) Mukherjee, a Ronald Finn Senior Research Fellow has become the first recipient of the prestigious Medical ...

ShareThe year 2024 etched an indelible mark on Nigeria’s economic history as over 20 highprofile multinational corporations, including Unilever Nigeria Plc, Procter & Gamble, GlaxoSmithKline Consumer ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

Innovative therapies revive a once-undruggable mitochondrial aging regulator through a revolutionary enzyme activation ...

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...

On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.